Clinical and biological moderators of response to naltrexone in alcohol dependence: A systematic review of the evidence

Addiction

Volumn 109, Issue 8, 2014, Pages 1274-1284

  Garbutt, James C ^a   Greenblatt, Amy M ^b   West, Suzanne L ^b   Morgan, Laura C ^b   Kampov Polevoy, Alexei ^a   Jordan, Harmon S ^b   Bobashev, Georgiy V ^b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b RTI INTERNATIONAL   (United States)

Author keywords

Alcohol dependence; Craving; Family history; Moderators; Naltrexone; OPMR1 Asn40Asp polymorphism

Indexed keywords

NALTREXONE; NARCOTIC ANTAGONIST;

ALCOHOLISM; HUMAN; TREATMENT OUTCOME;

ALCOHOLISM; HUMANS; NALTREXONE; NARCOTIC ANTAGONISTS; TREATMENT OUTCOME;

EID: 84903884663     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/add.12557     Document Type: Article

References (48)

1. Hasin D. S., Stinson F. S., Ogburn E., Grant B. F. Prevalence, correlates, disability, and comorbidity of DSM-IV alcohol abuse and dependence in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch Gen Psychiatry 2007; 64: 830-842.
2. Bouchery E. E., Harwood H. J., Sacks J. J., Simon C. J., Brewer R. D. Economic costs of excessive alcohol consumption in the U.S., 2006. Am J Prev Med 2011; 41: 516-524.
3. Mokdad A. H., Marks J. S., Stroup D. F., Gerberding J. L. Actual causes of death in the United States, 2000. JAMA 2004; 291: 1238-1245.
4. Miller W. R., Walters S. T., Bennett M. E. How effective is alcoholism treatment in the United States? J Stud Alcohol 2001; 62: 211-220.
5. Bouza C., Angeles M., Munoz A., Amate J. M. Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review [Provisional abstract]. Addiction 2004; 99: 811-828.
6. Garbutt J. C. Efficacy and tolerability of naltrexone in the management of alcohol dependence. Curr Pharm Des 2010; 16: 2091-2097.
7. Mark T. L., Kassed C. A., Vandivort-Warren R., Levit K. R., Kranzler H. R. Alcohol and opioid dependence medications: prescription trends, overall and by physician specialty. Drug Alcohol Depend 2009; 99: 345-349.
8. Kranzler H. R., Van Kirk J. Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis. Alcohol Clin Exp Res 2001; 25: 1335-1341.
9. Mark T. L., Kranzler H. R., Song X. Understanding US addiction physicians' low rate of naltrexone prescription. Drug Alcohol Depend 2003; 71: 219-228.
10. Kraemer H. C., Wilson G. T., Fairburn C. G., Agras W. S. Mediators and moderators of treatment effects in randomized clinical trials. Arch Gen Psychiatry 2002; 59: 877-883.
11. Wallace M. L., Frank E., Kraemer H. C. A novel approach for developing and interpreting treatment moderator profiles in randomized clinical trials. JAMA Psychiatry 2013; 70: 1241-1247.
12. Chamorro A. J., Marcos M., Miron-Canelo J. A., Pastor I., Gonzalez-Sarmiento R., Laso F. J. Association of micro-opioid receptor (OPRM1) gene polymorphism with response to naltrexone in alcohol dependence: a systematic review and meta-analysis. Addict Biol 2012; 17: 505-512.
13. Viswanathan M., Ansari M., Berkman N., Chang S., Hartling L., McPheeters M. etal. Assessing the Risk of Bias of Individual Studies in Systematic Reviews of Health Care Interventions. Rockville, MD: Agency for Healthcare Research and Quality Methods Guide for Comparative Effectiveness Reviews; 2012.
14. Owens D. K., Lohr K. N., Atkins D., Treadwell J. R., Reston J. T., Bass E. B. etal. AHRQ series paper 5: grading the strength of a body of evidence when comparing medical interventions-agency for healthcare research and quality and the effective health-care program. J Clin Epidemiol 2010; 63: 513-523.
15. Monterosso J. R., Flannery B. A., Pettinati H. M., Oslin D. W., Rukstalis M., O'Brien C. P. etal. Predicting treatment response to naltrexone: the influence of craving and family history. Am J Addict 2001; 10: 258-268.
16. Rubio G., Ponce G., Rodriguez-Jimenez R., Jimenez-Arriero M. A., Hoenicka J., Palomo T. Clinical predictors of response to naltrexone in alcoholic patients: who benefits most from treatment with naltrexone? Alcohol Alcohol 2005; 40: 227-233.
17. Rohsenow D. J., Miranda R. Jr, McGeary J. E., Monti P. M. Family history and antisocial traits moderate naltrexone's effects on heavy drinking in alcoholics. Exp Clin Psychopharmacol 2007; 15: 272-281.
18. Krishnan-Sarin S., Krystal J. H., Shi J., Pittman B., O'Malley S. S. Family history of alcoholism influences naltrexone-induced reduction in alcohol drinking. Biol Psychiatry 2007; 62: 694-697.
19. Capone C., Kahler C. W., Swift R. M., O'Malley S. S. Does family history of alcoholism moderate naltrexone's effects on alcohol use? J Stud Alcohol Drugs 2011; 72: 135-140.
20. Guardia J., Caso C., Arias F., Gual A., Sanahuja J., Ramirez M. etal. A double-blind, placebo-controlled study of naltrexone in the treatment of alcohol-dependence disorder: results from a multicenter clinical trial. Alcohol Clin Exp Res 2002; 26: 1381-1387.
21. Kiefer F., Helwig H., Tarnaske T., Otte C., Jahn H., Wiedemann K. Pharmacological relapse prevention of alcoholism: clinical predictors of outcome. Eur Addict Res 2005; 11: 83-91.
22. Garbutt J. C., Osborne M., Gallop R., Barkenbus J., Grace K., Cody M. etal. Sweet liking phenotype, alcohol craving and response to naltrexone treatment in alcohol dependence. Alcohol Alcohol 2009; 44: 293-300.
23. Jaffe A. J., Rounsaville B., Chang G., Schottenfeld R. S., Meyer R. E., O'Malley S. S. Naltrexone, relapse prevention, and supportive therapy with alcoholics: an analysis of patient treatment matching. J Consult Clin Psychol 1996; 64: 1044-1053.
24. Anton R. F., Oroszi G., O'Malley S., Couper D., Swift R., Pettinati H. etal. An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. Arch Gen Psychiatry 2008; 65: 135-144.
25. Oroszi G., Anton R. F., O'Malley S., Swift R., Pettinati H., Couper D. etal. OPRM1 Asn40Asp predicts response to naltrexone treatment: a haplotype-based approach. Alcohol Clin Exp Res 2009; 33: 383-393.
26. Kim S. G., Kim C. M., Choi S. W., Jae Y. M., Lee H. G., Son B. K. etal. A micro opioid receptor gene polymorphism (A118G) and naltrexone treatment response in adherent Korean alcohol-dependent patients. Psychopharmacology (Berl) 2009; 201: 611-618.
27. Oslin D. W., Berrettini W., Kranzler H. R., Pettinati H., Gelernter J., Volpicelli J. R. etal. A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology 2003; 28: 1546-1552.
28. Gelernter J., Gueorguieva R., Kranzler H. R., Zhang H., Cramer J., Rosenheck R. etal. Opioid receptor gene (OPRM1, OPRK1, and OPRD1) variants and response to naltrexone treatment for alcohol dependence: results from the VA Cooperative Study. Alcohol Clin Exp Res 2007; 31: 555-563.
29. Coller J. K., Cahill S., Edmonds C., Farquharson A. L., Longo M., Minniti R. etal. OPRM1 A118G genotype fails to predict the effectiveness of naltrexone treatment for alcohol dependence. Pharmacogenet Genomics 2011; 21: 902-905.
30. Kiefer F., Witt S. H., Frank J., Richter A., Treutlein J., Lemenager T. etal. Involvement of the atrial natriuretic peptide transcription factor GATA4 in alcohol dependence, relapse risk and treatment response to acamprosate. Pharmacogenomics J 2011; 11: 368-374.
31. Anton R. F., O'Malley S. S., Ciraulo D. A., Cisler R. A., Couper D., Donovan D. M. etal. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA 2006; 295: 2003-2017.
32. Greenfield S. F., Pettinati H. M., O'Malley S., Randall P. K., Randall C. L. Gender differences in alcohol treatment: an analysis of outcome from the COMBINE study. Alcohol Clin Exp Res 2010; 34: 1803-1812.
33. Baros A. M., Latham P. K., Anton R. F. Naltrexone and cognitive behavioral therapy for the treatment of alcohol dependence: do sex differences exist? Alcohol Clin Exp Res 2008; 32: 771-776.
34. Garbutt J. C., Kranzler H. R., O'Malley S. S., Gastfriend D. R., Pettinati H. M., Silverman B. L. etal. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial. JAMA 2005; 293: 1617-1625.
35. Kiefer F., Jahn H., Wiedemann K. A neuroendocrinological hypothesis on gender effects of naltrexone in relapse prevention treatment. Pharmacopsychiatry 2005; 38: 184-186.
36. Kranzler H. R., Tennen H., Armeli S., Chan G., Covault J., Arias A. etal. Targeted naltrexone for problem drinkers. J Clin Psychopharmacol 2009; 29: 350-357.
37. Pettinati H. M., Silverman B. L., Battisti J. J., Forman R., Schweizer E., Gastfriend D. R. Efficacy of extended-release naltrexone in patients with relatively higher severity of alcohol dependence. Alcohol Clin Exp Res 2011; 35: 1804-1811.
38. Gueorguieva R., Wu R., Donovan D., Rounsaville B. J., Couper D., Krystal J. H. etal. Baseline trajectories of drinking moderate acamprosate and naltrexone effects in the COMBINE study. Alcohol Clin Exp Res 2011; 35: 523-531.
39. Gueorguieva R., Wu R., Donovan D., Rounsaville B. J., Couper D., Krystal J. H. etal. Naltrexone and combined behavioral intervention effects on trajectories of drinking in the COMBINE study. Drug Alcohol Depend 2010; 107: 221-229.
40. Krystal J. H., Gueorguieva R., Cramer J., Collins J., Rosenheck R., Team V. C. N. S. Naltrexone is associated with reduced drinking by alcohol dependent patients receiving antidepressants for mood and anxiety symptoms: results from VA Cooperative Study no. 425, 'Naltrexone in the treatment of alcoholism'. Alcohol Clin Exp Res 2008; 32: 85-91.
41. Bogenschutz M. P., Scott Tonigan J., Pettinati H. M. Effects of alcoholism typology on response to naltrexone in the COMBINE study. Alcohol Clin Exp Res 2009; 33: 10-18.
42. Laaksonen E., Lahti J., Sinclair J. D., Heinala P., Alho H. Predictors for the efficacy of naltrexone treatment in alcohol dependence: sweet preference. Alcohol Alcohol 2011; 46: 308-311.
43. Ishikawa K. Guide to Quality Control. New York: Quality Resources; 1968.
44. Kranzler H. R., Armeli S., Covault J., Tennen H. Variation in OPRM1 moderates the effect of desire to drink on subsequent drinking and its attenuation by naltrexone treatment. Addict Biol 2013; 18: 193-201.
45. Anton R. F., Voronin K. K., Randall P. K., Myrick H., Tiffany A. Naltrexone modification of drinking effects in a subacute treatment and bar-lab paradigm: influence of OPRM1 and dopamine transporter (SLC6A3) genes. Alcohol Clin Exp Res 2012; 36: 2000-2007.
46. Schacht J. P., Anton R. F., Voronin K. E., Randall P. K., Li X., Henderson S. etal. Interacting effects of naltrexone and OPRM1 and DAT1 variation on the neural response to alcohol cues. Neuropsychopharmacology 2013; 38: 414-422.
47. Ramchandani V. A., Umhau J., Pavon F. J., Ruiz-Velasco V., Margas W., Sun H. etal. A genetic determinant of the striatal dopamine response to alcohol in men. Mol Psychiatry 2011; 16: 809-817.
48. Rice J. P., Reich T., Bucholz K. K., Neuman R. J., Fishman R., Rochberg N. etal. Comparison of direct interview and family history diagnoses of alcohol dependence. Alcohol Clin Exp Res 1995; 19: 1018-1023.